Reply: “Exploring Safety in Gender-Affirming Hormonal Treatments: An Observational Study on Adverse Drug Events Using the Food and Drug Administration Adverse Event Reporting System Database”
Restricted accessReplyFirst published online May, 2025
Reply: “Exploring Safety in Gender-Affirming Hormonal Treatments: An Observational Study on Adverse Drug Events Using the Food and Drug Administration Adverse Event Reporting System Database”
Gomez-LumbrerasAVilla-ZapataL.Exploring safety in gender-affirming hormonal treatments: an observational study on adverse drug events using the food and drug administration adverse event reporting system database [published online ahead of print February 12, 2024]. Ann Pharmacother. doi:10.1177/10600280241231612
2.
RestarADusicEJGarrison-DesanyH, et alGender affirming hormone therapy dosing behaviors among transgender and nonbinary adults. Humanit Soc Sci Commun. 2022;9(1):304. doi:10.1057/s41599-022-01291-5
HembreeWCCohen-KettenisPTGoorenL, et alEndocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869-3903. doi:10.1210/jc.2017-01658
5.
HallRCWHallRCWChapmanMJ. Psychiatric complications of anabolic steroid abuse. Psychosomatics. 2005;46(4):285-290. doi:10.1176/appi.psy.46.4.285
6.
Clements-NolleKMarxRKatzM.Attempted suicide among transgender persons: the influence of gender-based discrimination and victimization. J Homosex. 2006;51(3):53-69. doi:10.1300/J082v51n03_04
7.
ChenDBeronaJChanYM, et alPsychosocial functioning in transgender youth after 2 years of hormones. N Engl J Med. 2023;388(3):240-250. doi:10.1056/NEJMoa2206297
8.
BiggsM.Psychosocial functioning in transgender youth after hormones. N Engl J Med. 2023;389(16):1536-1537. doi:10.1056/NEJMc2302030
9.
Chan SweNAhmedSEidMPoretskyLGianosECusanoNE. The effects of gender-affirming hormone therapy on cardiovascular and skeletal health: a literature review. Metabol Open. 2022;13:100173. doi:10.1016/j.metop.2022.100173
